Realm Therapeutics logo

RLM - Realm Therapeutics Share Price

11.5p 0.0  0.0%

Last Trade - 26/03/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £208k
Position in Universe th / 1827
Bullish
Bearish
Unlock RLM Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2018, Realm Therapeutics PLC revenues decreased 77% to $253K. Net loss increased 29% to $13.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.16 to -$0.12.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RLM Revenue Unlock RLM Revenue

Net Income

RLM Net Income Unlock RLM Revenue

Normalised EPS

RLM Normalised EPS Unlock RLM Revenue

PE Ratio Range

RLM PE Ratio Range Unlock RLM Revenue

Dividend Yield Range

RLM Dividend Yield Range Unlock RLM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RLM EPS Forecasts Unlock RLM Revenue
Profile Summary

Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology. The Company has developed proprietary formulations of its technology, with anti-inflammatory and immunomodulatory benefits. Its pipeline of products include PR013 and PR022, which are in Phase I. PR013 is indicated for allergic conjunctivitis and PR022 is indicated for atopic dermatitis. Realm Therapeutics, Inc. is a subsidiary of the Company.

Directors
Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated April 21, 2006
Public Since June 30, 2006
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange
Shares in Issue 116,561,917
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RLM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to RLM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.